peanut-allergy Aimmune TherapeuticsAR101

Aimmune Therapeutics begins Phase II trial of AR101 and dupilumab

Aimmune Therapeutics has started a Phase II trial of AR101 with adjunctive dupilumab for the treatment of patients with peanut…